This article covers PicoSure's mechanism, the published evidence, candidacy, risks, the treatment process, aftercare, and alternatives. It does not promise permanent removal, because no study supports that.
Treatment decisions should follow an in-person diagnosis by a qualified US clinician. Melasma can resemble other pigmentary conditions, and laser settings affect risk.
Key Takeaways
- PicoSure may reduce visible melasma in selected patients, but it won't remove the tendency to make pigment.
- Diagnosis, skin type, settings, sun protection, and clinician experience matter as much as the device name.
- Judge evidence by wavelength, device, and melasma protocol, not by "pico laser" claims in general.
- Ask about alternatives, post-inflammatory hyperpigmentation (PIH), maintenance, and what FDA documentation covers.
What PicoSure Is and What It Can Do for Melasma
The platform and its mechanism
PicoSure is a branded picosecond laser platform from Cynosure. PicoSure Pro delivers 755 nm energy, with optional 532 nm and 1064 nm systems. Peer-reviewed work describes its action as mainly photomechanical, shattering pigment with less heat spread.
Heat and inflammation can still occur. Energy, wavelength, fluence, spot size, and repetition rate still shape tissue response. Listed 755 nm specifications include 500-900 ps pulses and spot sizes of 2-6 mm zoom or fixed 5, 6, 8, and 10 mm.
Why melasma is hard to clear
Melasma is multifactorial. Hormones, ultraviolet light, visible light, genetics, inflammation, and vascular signaling all play roles. Heat exposure shows observational associations only.
Breaking up existing pigment doesn't stop new pigment from forming. That's why recurrence is the central problem.
Diagnosis matters too. PIH, solar lentigines, and freckles can look similar, and the American Academy of Dermatology notes that mimics occasionally need a biopsy. Results for pigmented lesions don't automatically apply to melasma.
What the studies show
The best branded evidence is modest:
- 2023 randomized trial: Week-24 MASI fell 25.5% with PicoSure vs 24.0% with 2% hydroquinone in 60 women (Fitzpatrick III-IV); no significant difference. PIH in 1 of 20; recurrence in 2 of 20.
- 2022 split-face trial: adding a 755 nm picosecond laser to 2% hydroquinone gave no significant added benefit, and 15% had mild PIH on the laser side.
- 2024 two-year study: a 755 nm comparison found 58.82% of retained patients reported recurrence or exacerbation.
- 2023 meta-analysis: six trials, high heterogeneity, and the 755 nm subgroup wasn't superior to topical agents.
All of these trials were small and short-term. None established long-term control, and type V-VI skin was not studied in the branded trial.
FDA clearance in context
FDA labeling lists melasma under 755 nm. A 510(k) clearance means substantial equivalence to a legally marketed device, per FDA. It is not proof of permanent clearance or superiority over topicals. Verify the exact model, handpiece, and indication, since the Platinum Focus lens carries acne scar and wrinkle wording instead.
Who Might Be a Candidate? Safety, Risks, and Contraindications
What a consultation should assess
- Confirmed diagnosis and melasma pattern
- Fitzpatrick skin type and prior pigmentary reactions
- Current skincare, recent tanning, and sun exposure
- Medications, pregnancy, and hormonal changes
- Ability to follow strict sun protection
The 2023 trial excluded active-stage melasma, pregnancy and lactation, photosensitive conditions, and recent oral sulfonamides or tetracyclines. Those were study rules, not universal ones, but they show where evidence stops.
Darker skin and PIH history
The branded trial enrolled types III-IV only. Its 5% PIH rate is not a benchmark for types V-VI.
Darker skin is more prone to dyspigmentation, blistering, and scarring after cosmetic lasers. These patients may need test spots, conservative settings, or a different first-line approach. Dr. Kenneth Thean notes that picosecond lasers can cause hyperpigmentation and that settings need adjusting for each patient.
Possible adverse effects
- Temporary redness, swelling, tenderness, and sensitivity
- Darkening, lightening, or uneven response
- PIH, hypopigmentation, blistering, and scarring
- Rebound or paradoxical worsening
- Ocular injury without proper eye protection
In the 2023 trial, PIH resolved within 1-6 months. Small arms don't prove zero risk.
Postponement and clinician discretion
Active infection, inflammation, recent tanning, and impaired healing call for clinician judgment. On isotretinoin, a 2017 ASDS consensus found insufficient evidence for routine delay of nonablative lasers, though practices vary. Confirm against device labeling.
Questions to ask your clinician
- What is your experience with melasma and skin of color?
- Will you do a test spot, and with what settings and wavelength?
- What recurrence should I expect?
- Whom do I contact in an emergency?
- Will you take before-and-after photos?
- What is the plan if pigment worsens?
Topicals and photoprotection often come before or alongside laser. A patient who can't follow aftercare has a worse risk-benefit profile.
How PicoSure Treatment Is Performed and Managed Afterward
Preparation and the procedure
- Consult: confirm diagnosis, take baseline photos, review medications and skincare, and set realistic goals.
- Plan: choose wavelength and settings, and decide on a test spot or staged approach.
- Treat: cleanse the skin, protect the eyes, and deliver pulses to the selected areas.
Sensations, duration, and comfort measures vary by protocol. A 2025 expert consensus calls for lubricated stainless-steel eye shields and stopping at once for ocular pain or vision changes.
Sessions and spacing
No single session count fits every case. Published schedules differ:
- Branded PicoSure trial: 3 sessions at 4-week intervals
- 2022 755 nm study: 5 sessions every 2 weeks
- 2024 study: 3 monthly sessions
Your clinician should individualize based on response and skin reaction.
Aftercare
- Cleanse gently and use barrier-supportive skincare
- Apply broad-spectrum SPF 30+ daily, ideally with iron oxide for visible-light protection
- Avoid heat, picking, and irritating products
- Follow your clinician's written instructions
Visible-light protection matters. In a 68-patient trial, UV-plus-visible sunscreen with hydroquinone gave 15% greater MASI improvement at 8 weeks than UV-only sunscreen.
Judging results
Compare consistent photographs over months, not immediate lightening. Temporary darkening, gradual improvement, recurrence, and maintenance needs are all possible.
Call the clinic promptly for:
- Severe or increasing pain
- Blistering or signs of infection
- Marked swelling or persistent inflammation
- Significant color change or rapidly worsening melasma
PicoSure Compared With Other Melasma Treatments
Foundational management
The American Academy of Dermatology (AAD) calls sun protection plus medication foundational. Options include hydroquinone, tretinoin with a mild steroid, triple combinations, and tranexamic acid (with blood-clot history reviewed).
These address ongoing pigment stimulation. Lasers mainly target existing pigment.
Fractional CO2
CO2 is ablative and thermal, with several days of downtime, while picosecond treatment is non-ablative. That does not make CO2 automatically stronger for melasma.
A 2019 trial found adding fractional CO2 to 4% hydroquinone gave no significant advantage over hydroquinone alone, though results from earlier small trials conflict. Follow-up in these studies was only 2-3 months, and none compared CO2 head-to-head with PicoSure.
HydraFacial, IPL, and Q-switched lasers
- HydraFacial: superficial cleansing and exfoliation. A small 2024 imaging study of 8 volunteers had no melasma efficacy endpoint.
- IPL: a 2004 controlled study showed greater melanin improvement with IPL plus hydroquinone, but partial repigmentation followed.
- Q-switched: a 2024 trial showed no significant difference from 755 nm picosecond, and recurrence was substantial.
No modality is universally superior.
How Clinicians and Practice Owners Should Evaluate PicoSure for Melasma
A device checklist
- Exact model, wavelengths, and handpieces
- Pulse duration, spot sizes, energy, and repetition ranges
- Manufacturer indications for each optic
- Training requirements, servicing, and warranty terms
- Consumables and treatment documentation
FDA lists the device for prescription use. ASLMS expects physician and staff training and a facility laser-safety program, but neither sets minimum PicoSure-specific training hours. One FDA workstation record lists 1, 2.5, 5, and 10 Hz repetition rates; confirm what your configuration offers.
Separate marketing from evidence
Review peer-reviewed melasma studies for the skin types you intend to treat. Compare patient populations, treatment parameters, follow-up length, and reported outcomes. Adverse-event databases need careful reading, since FDA says MAUDE reports cannot establish incidence or causation.
Where the Buyer's Guide fits
The Pico Laser Buyer's Guide is an independent educational resource. It offers manufacturer-backed documentation, comparative research across 16 pico laser platforms, and FDA 510(k) verification resources. Use it as procurement support, not as a substitute for clinical judgment or a recommendation to buy PicoSure.
Frequently Asked Questions
Will Pico laser remove melasma?
It may improve visible melasma for some patients, but it can't guarantee permanent removal or prevent recurrence. Diagnosis, trigger control, and individualized planning shape results.
What is the best laser for treating melasma?
No laser is universally best. The choice depends on diagnosis, skin type, pigment depth, prior response, available evidence, and the clinician's risk management.
How is Pico laser treatment performed?
After consultation and skin assessment, the eyes are protected and selected pulses are delivered. Sensations vary, sessions are individualized, and strict photoprotection follows.
How does PicoSure compare with CO2 laser or HydraFacial for melasma?
PicoSure targets pigment non-ablatively, CO2 resurfaces through ablation, and HydraFacial exfoliates superficially. Evidence, risks, downtime, and goals differ.
Can PicoSure make melasma worse?
Yes. Any energy-based treatment can cause inflammation, PIH, rebound darkening, or uneven results in susceptible patients. Accurate diagnosis, conservative settings, test spots, and aftercare reduce that risk.
How many PicoSure sessions are needed for melasma?
There's no reliable universal number. It depends on response, skin reaction, protocol, severity, and whether other medical management is combined.
